Kenbei Miao (02161.HK) cancelled 350,000 shares and repurchased shares on April 24
Gelonghui, April 24, 丨 Jianbei Miao Miao (02161.HK) issued an announcement to cancel 350,000 repurchased shares on April 24, 2024.
Zhitong Hong Kong Stock Repurchase Statistics|April 12
Hong Kong Stock Repurchase Statistics|April 12
Kenbei Miao Miao (02161.HK) spent HK$151,400 to buy back 170,000 shares on April 11
On April 11, GLONGHUI (02161.HK) issued an announcement. On April 11, 2024, it spent HK$151,400 to repurchase 170,000 shares, with a repurchase price of HK$0.887143-0.9 per share.
Kenbei Miao Miao (02161.HK) bought back 10,000 shares on April 10
On April 10, GLONGHUI (02161.HK) issued an announcement. On April 10, 2024, 10,000 shares were repurchased at HK$9040 at a repurchase price of HK$0.904 per share.
Kenbei Miao Miao (02161.HK) spent HK$116,000 to buy back 130,000 shares on April 9
Gelonghui, April 9, 丨 Jianbei Miao Miao (02161.HK) issued an announcement. On April 9, 2024, it spent HK$116,000 to repurchase 130,000 shares at a repurchase price of HK$0.891-0.892 per share.
Kenbei Miao Miao (02161.HK) spent HK$25,700 to buy back 28,000 shares on April 5
Gelonghui announced on April 5: Jianbei Miao Miao (02161.HK) announced that it spent HK$25,700 to repurchase 28,000 shares on April 5.
Kenbei Miao (02161) spent HK$10,700 to buy back 12,000 shares on March 28
Kenbei Miao (02161) announced that on March 28, 2024, the company spent HK$10,700 to return...
Selected Announcements | Country Garden was petitioned for liquidation by Ever Credit; China Exempts China to invest an additional 1.1 billion yuan in duty-free shopping
Nine Dragons Paper announced interim results, with shareholders accounting for a profit of 292 million yuan, turning a year-on-year loss into a profit; Fuzhikang Group issued a profit warning and expects a consolidated net loss of about US$120.8 million in 2023.
Kenbei Miao (02161.HK) cancelled 3.662 million shares and repurchased shares on February 27
On February 27, Gelonghui | Jianbei Miaomiao (02161.HK) issued an announcement to cancel 3.662 million shares purchased on February 27, 2024.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
On January 17, Kenbei Miao spent about HK$17.23,800 to buy back 16.462 million shares
Kenbei Miao (02161) announced that on January 17, 2024, it spent approximately HK$17.23,800 to repurchase 16.462 million shares.
Kenbei Miao Miao (02161) spent about HK$17.238,800 to buy back 16.462 million shares on January 17
Kenbei Seedling (02161) announced that on January 17, 2024, it cost about HK$17.23,800 to buy back 16...
Kenbei Miao Miao (02161.HK) spent HK$1.53 million to buy back 14.4 million shares on January 16
On January 16, Gelonghui announced that on January 16, Jianbei Miao Miao (02161.HK) purchased 14.4 million shares at HK$1.53 million on January 16.
Kenbei Miao spent HK$815,500 to buy back 800,000 shares on January 15
Kenbei Miao Miao (02161) announced that it spent HK$815,500 to repurchase 800,000 shares on January 15, 2024.
Kenbei Miao (02161) spent HK$815,500 to buy back 800,000 shares on January 15
Kenbei Seedling (02161) issued an announcement to repurchase 80 at HK$815,500 on January 15, 2024...
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
JBM HEALTHCARE: Interim Report 2023
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
No Data